Europe. Even the previously reported distributions of autism risk score of AGRE individuals with and without the disorder 1 are consistent with this explanation (Supplementary Data).
As we found that autism risk scores based on the publicly available SNPs did not distinguish independent cases from controls, we asked if these score distributions differed between European populations. CEU (the control group used to train the classifier) had the lowest median and mean autism risk scores of these European populations (1.3 and 1.4, respectively) whereas Finns, a representative Northeastern European population, had the highest median and mean autism risk scores (2.8 and 2.7, respectively), as would be expected if the classifier were confounded by population structure. Their overall distributions also differed (two-sample K-S test, P = 0.0005).
In the publication describing the classifier, an autism risk score cutoff of 3.93 was used to predict affectation status. We examined the properties of our populations using this cutoff, although we note that as we had data only on 19 of the 30 SNPs, it is an approximation of the results based on the 30 SNP classifier. 1 Importantly, the proportion of Finns above this autism risk score cutoff (29%) differed neither from AGRE cases (28%) nor AGRE controls (31%) (two-tailed Fisher's exact tests P = 0.89 and P = 0.81, respectively). In contrast, more Finns were classified as autistic than the training HapMap3 population CEU (12%; two-tailed Fisher's exact test P = 0.0054), the independent 1000 Genomes British population GBR (17%; two-tailed Fisher's exact test P = 0.055) and the HapMap3 Italian population TSI (16%; twotailed Fisher's exact test P = 0.039). These analyses lead to the conclusion that the autism risk scores based on the publicly available SNPs effectively separate European populations from one another, but do not separate cases from controls. Moreover, as Northeastern Europeans generally had higher scores than Western or Southern Europeans, this would result in inflated measures of accuracy in the previously reported independent validation that used diverse European Americans as cases and Northwestern Europeans as controls. 1 Whereas these strongest contributors to the classifier are more consistent with artifacts of population structure than with true autism spectrum disorder signal, it remains possible that there are some true signals differentiating cases and controls, particularly among the 207 weaker SNPs that are not currently publicly available. However, until more evidence can be provided, we favor the more conservative interpretation that these associations are due to previously unobserved population stratification in the cases and controls, and do not contribute meaningfully to a diagnostic classifier.
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We wrote to Dr Belgard who kindly provided the 19 singlenucleotide polymorphisms (SNPs) used in their analysis. 1 These 19 SNPs were derived from the 30 SNPs provided in our original article. Of these 19 SNPs, the number of SNPs with positive weights exceeded the number of SNPs with negative weights, including the second most negative weighted SNP, rs12317962, on KCNMB4, which would bias the classifier score. Our original analyses included a total of 237 SNPs. In order to address the issue of ethnic population stratification, we downloaded data from the 1000 genome cohort, 3 including Central European (CEU), Finnish (FIN), Great British (GBR) and Iberian Spanish (IBS) populations.
In their analysis using 19 SNPs, Belgard et al. indicated that in Finns (non-autism spectrum disorder (ASD)), our classifier had a higher chance of classifying individuals as ASD compared with CEU (non-ASD) individuals. They concluded that our classifier might be better at separating between European subpopulations than cases from controls. In order to examine this in detail, we tested our classifier performance in correctly identifying control individuals from the CEU, FIN, GBR and IBS control populations. As not all SNPs were available across all data sets, we retrained the classifier using the common SNPs on our training set and then applied the classifier on unseen validation data from the FIN, GBR and IBS control cohorts. Comparing these ethnic European subpopulations, we found that greater differences in classifier score between these populations occurred when only part of the classifier was used (a difference as high as 25% was observed between the FIN and GBR groups). However, using the full classifier, the effects of ethnic population contributed to o6% of the total difference in classifier score. We also provide the full 237 SNPs relevant to our classifier ( Table 1 ). The full code used in the generation of the classifier has been made available on the Autism Genetic Resource Exchange (AGRE) website (http://agre.org), together with testing of the classifier on other ASD data sets. Using our SNPs, we then examined their predictive accuracy in classifying control individuals from the FIN and GBR (non-ASD) populations, as well as SFARI (Simons Foundation Autism Research Initiative) ASD probands (the independent validation sample in our paper). We plotted the percentage of individuals classified as Letters to the Editor ASD against the number of SNPs used in the classifier, with SNPs ordered by absolute magnitude of their weightings. As can be seen in Figure 1 , while population stratification may have an influence at lower SNP numbers with regard to differences in classifier accuracy between populations, such an effect is diminished as a greater number of SNPs are included. The separation in percentage classified as ASD between the SFARI/ASD and the FIN/GBR groups occurred with increasing gradient between 50 and 100 SNPs, whereas at >150 SNPs the separation between these groups plateaus. This is to be expected, as these SNPs have the smallest weightings within the classifier. Therefore, in keeping with Belgard et al's analysis, we show that at low SNP numbers, population effects may influence classification accuracy, but these effects are of second order to the ASD signal as the number of SNPs increases. Using the classifier, as described above, we tested its accuracy in correctly classifying controls (non-ASD) within individual European cohorts. We achieved accuracies (that is, correct classification as non-ASD) of 82% for the FIN, 78% for GBR and 67% for the Spanish cohorts. In addition, to determine classifier performance confidence intervals, we performed a bootstrap analysis (1000 permutations were undertaken; 80% of the data was used to train a classifier to predict the remaining 20%) on all white non-hispanic populations, including all available populations (that is, SFARI and Autism Genetic Resource Exchange probands, and WTBC, CEU, FIN, GBR and IBS Controls). Diagnostic accuracy for ASD was 66.0% (90% CI: 61.5-71.9), with a sensitivity of 63.4% (90% CI: 54.3-75.9) and specificity of 67.2% (90% CI: 59.5-74.3). This equates to a positive likelihood ratio of 1.9 (90% CI: 1.3-3.0).
In our paper, we reported positive and negative predictive accuracies that were 70.8% and 71.8%, respectively. 2 Based on a population prevalence of 1:88 cases of ASD in the US population, 4 this equates to a positive predictive value (that is, precision) of 2.8% and a negative predictive value of 99.5%. This suggests that the classifier is not suitable as a general screening method, rather it should only be considered in high-risk populations where the base rate of ASD is high and produces acceptable positive and negative predictive values.
In conclusion, we demonstrate that the SNPs in our classifier show some ability to non-randomly distinguish between ASD and controls and that our results are not merely explained by population stratification as demonstrated in our analyses in independent cohorts of individuals of European ancestry. Further work on such approaches is needed in order to validate these findings, for example, prospective studies that examine children at risk for ASD (such as families with an affected member). 
